MX2013002379A - Moleculas de union a vegf. - Google Patents
Moleculas de union a vegf.Info
- Publication number
- MX2013002379A MX2013002379A MX2013002379A MX2013002379A MX2013002379A MX 2013002379 A MX2013002379 A MX 2013002379A MX 2013002379 A MX2013002379 A MX 2013002379A MX 2013002379 A MX2013002379 A MX 2013002379A MX 2013002379 A MX2013002379 A MX 2013002379A
- Authority
- MX
- Mexico
- Prior art keywords
- vegf
- binding molecules
- binding
- anddomain
- vhhs
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Mycology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Moléculas de unión a VEGF, preferiblemente dominios variables individuales de inmunoglobulina de unión a VEGF tales como los VHHs y los anticuerpos de dominio, composiciones farmacéuticas que contienen los mismos y su uso en el tratamiento de enfermedades que están asociadas con los efectos sobre la angiogénesis mediados por el VEGF. Ácidos nucleicos que codifican moléculas de unión a VEGF, células hospedantes y métodos para la preparación de los mismos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10175318 | 2010-09-03 | ||
PCT/EP2011/065199 WO2012028716A1 (en) | 2010-09-03 | 2011-09-02 | Vegf-binding molecules |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2013002379A true MX2013002379A (es) | 2013-05-09 |
MX353813B MX353813B (es) | 2018-01-31 |
Family
ID=43530923
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2013002379A MX353813B (es) | 2010-09-03 | 2011-09-02 | Moleculas de union a vegf. |
Country Status (16)
Country | Link |
---|---|
US (6) | US20120225081A1 (es) |
EP (2) | EP2611830A1 (es) |
JP (1) | JP5979504B2 (es) |
KR (1) | KR101844875B1 (es) |
CN (1) | CN103209995B (es) |
AR (1) | AR082892A1 (es) |
AU (1) | AU2011298281B2 (es) |
BR (1) | BR112013005151A2 (es) |
CA (1) | CA2808696C (es) |
CL (1) | CL2013000596A1 (es) |
EA (1) | EA029277B1 (es) |
IL (1) | IL224800B (es) |
MX (1) | MX353813B (es) |
NZ (1) | NZ607394A (es) |
UY (1) | UY33588A (es) |
WO (1) | WO2012028716A1 (es) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9527925B2 (en) | 2011-04-01 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to VEGF and ANG2 |
WO2014031856A1 (en) * | 2012-08-23 | 2014-02-27 | Onconthyreon Inc. | Combination therapy using pi3 kinase and braf inhibitors |
KR101541478B1 (ko) * | 2013-05-31 | 2015-08-05 | 동아쏘시오홀딩스 주식회사 | 항-vegf 항체 및 이를 포함하는 암 또는 신생혈관형성관련 질환의 예방, 진단 또는 치료용 약학 조성물 |
US9388239B2 (en) * | 2014-05-01 | 2016-07-12 | Consejo Nacional De Investigation Cientifica | Anti-human VEGF antibodies with unusually strong binding affinity to human VEGF-A and cross reactivity to human VEGF-B |
AU2015376558B9 (en) * | 2015-01-06 | 2021-07-01 | Zhuhai Essex Bio-Pharmaceutical Co., Ltd. | Anti-VEGF antibody |
JP7195927B2 (ja) * | 2016-03-08 | 2022-12-26 | 武田薬品工業株式会社 | 誘導性結合タンパク質及びその使用方法 |
WO2018046997A2 (en) * | 2016-09-07 | 2018-03-15 | Saksin Lifesciences Pvt Ltd | Synthetic antibodies against vegf and their uses |
TW201840584A (zh) * | 2017-03-20 | 2018-11-16 | 美商歐樂根公司 | 針對vegf之僅含重鏈之抗體 |
BR112020004543A2 (pt) | 2017-09-08 | 2020-09-08 | Maverick Therapeutics, Inc. | proteínas de ligação ativadas condicionalmente restritas |
US11685780B2 (en) | 2019-03-05 | 2023-06-27 | Takeda Pharmaceutical Company Limited | Single domain antigen binding domains that bind human Trop2 |
CN110452297B (zh) * | 2019-09-03 | 2020-04-14 | 上海洛启生物医药技术有限公司 | 抗vegf单域抗体及其应用 |
JP2023536652A (ja) | 2020-08-05 | 2023-08-28 | シンセカイン インコーポレイテッド | IL27Rα結合分子および使用方法 |
CN117279941A (zh) * | 2021-02-19 | 2023-12-22 | 多特生物私人有限公司 | Vegfa结合分子 |
EP4386004A1 (en) * | 2021-08-13 | 2024-06-19 | Innovent Biologics (Suzhou) Co., Ltd. | Anti-vegf a and -vegf c bispecific antibody and use thereof |
CN115724968B (zh) * | 2021-08-27 | 2023-08-08 | 三优生物医药(上海)有限公司 | Vegf结合分子及其用途 |
CN113896805B (zh) * | 2021-12-13 | 2022-02-25 | 上海惠盾因泰生物科技有限公司 | 一种vegf-crm197重组融合蛋白疫苗及其制备方法和应用 |
WO2024055996A1 (zh) * | 2022-09-14 | 2024-03-21 | 寻济生物科技(北京)有限公司 | 一种抗vegfa抗体或其抗原结合片段及其应用 |
CN116284405B (zh) * | 2023-03-15 | 2024-03-19 | 中国科学技术大学 | 靶向cd150蛋白的纳米抗体及其应用 |
CN118085081B (zh) * | 2024-04-19 | 2024-06-21 | 云南大学 | 一种特异性结合vegf的纳米抗体及用途 |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0656946B2 (en) | 1992-08-21 | 2010-03-31 | Vrije Universiteit Brussel | Immunoglobulins devoid of light chains |
EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
US6884879B1 (en) * | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
US6329516B1 (en) | 1997-04-28 | 2001-12-11 | Fmc Corporation | Lepidopteran GABA-gated chloride channels |
WO2001079480A1 (en) | 2000-04-12 | 2001-10-25 | Human Genome Sciences, Inc. | Albumin fusion proteins |
EP1361892A4 (en) | 2001-01-17 | 2004-10-13 | Trubion Pharmaceuticals Inc | BINDING DOMAIN FUSION PROTEIN Immunoglobulin |
JP4303105B2 (ja) | 2001-06-28 | 2009-07-29 | ドマンティス リミテッド | 二重特異性リガンドとその利用 |
WO2003059934A2 (en) | 2001-12-21 | 2003-07-24 | Human Genome Sciences, Inc. | Albumin fusion proteins |
EP2284192A3 (en) | 2002-11-08 | 2011-07-20 | Ablynx N.V. | Camelidae antibodies for sublingual administration |
US20050043220A1 (en) * | 2002-11-08 | 2005-02-24 | Guyer David R. | Methods and compositions for treating macular degeneration |
WO2004041867A2 (en) | 2002-11-08 | 2004-05-21 | Ablynx N.V. | Camelidae antibodies against imminoglobulin e and use thereof for the treatment of allergic disorders |
JP4490290B2 (ja) | 2002-12-31 | 2010-06-23 | ネクター セラピューティクス アラバマ,コーポレイション | 加水分解安定性マレイミド末端ポリマー |
PT1639011E (pt) | 2003-06-30 | 2009-01-20 | Domantis Ltd | Anticorpos (dab) de domínio único peguilados |
EP1687338B1 (en) | 2003-11-07 | 2010-10-20 | Ablynx N.V. | Camelidae single domain antibodies vhh directed against epidermal growth factor receptor and uses thereof |
US20050284249A1 (en) | 2004-06-29 | 2005-12-29 | Arnone David F | Worm type gear mover assembly |
RU2007117752A (ru) | 2004-10-13 | 2008-11-20 | Аблинкс Н.В. (Be) | Нанотела (nanobodies тм) против бета-амилоида и полипептидов, содержащих бета-амилоид, для лечения нейродегенеративных заболеваний, таких как болезнь альцгеймера |
BR122013001996B1 (pt) | 2005-05-18 | 2022-02-01 | Ablynx N.V. | Nanocorpos melhorados contra fator alfa de necrose tumoral |
KR20090016762A (ko) | 2006-06-06 | 2009-02-17 | 제넨테크, 인크. | 혈관 발달을 조정하기 위한 조성물 및 방법 |
AU2007285695B2 (en) | 2006-08-18 | 2012-05-24 | Ablynx N.V. | Amino acid sequences directed against IL-6R and polypeptides comprising the same for the treatment of diseases and disorders associated with IL-6-mediated signalling |
JP2010507594A (ja) * | 2006-10-20 | 2010-03-11 | シェーリング コーポレイション | 完全ヒト抗vegf抗体および使用方法 |
JP2010518839A (ja) * | 2007-02-21 | 2010-06-03 | アブリンクス エン.ヴェー. | 血管内皮増殖因子に指向性を有するアミノ酸配列、及び過度の及び/もしくは病的な血管形成又は血管新生を特徴とする症状及び疾患を治療するためにこれを含むポリペプチド |
CA2702637A1 (en) | 2007-10-22 | 2009-04-30 | Schering Corporation | Fully human anti-vegf antibodies and methods of using |
WO2009095489A2 (en) | 2008-02-01 | 2009-08-06 | Ablynx N.V. | Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling |
AU2009221106A1 (en) | 2008-03-05 | 2009-09-11 | Ablynx Nv | Novel antigen binding dimer-complexes, methods of making and uses thereof |
WO2010124009A2 (en) * | 2009-04-21 | 2010-10-28 | Schering Corporation | Fully human anti-vegf antibodies and methods of using |
UY32920A (es) * | 2009-10-02 | 2011-04-29 | Boehringer Ingelheim Int | Moleculas de unión biespecíficas para la terapia anti-angiogénesis |
-
2011
- 2011-09-01 US US13/223,563 patent/US20120225081A1/en not_active Abandoned
- 2011-09-02 WO PCT/EP2011/065199 patent/WO2012028716A1/en active Application Filing
- 2011-09-02 JP JP2013526488A patent/JP5979504B2/ja active Active
- 2011-09-02 CN CN201180052278.8A patent/CN103209995B/zh active Active
- 2011-09-02 MX MX2013002379A patent/MX353813B/es active IP Right Grant
- 2011-09-02 AU AU2011298281A patent/AU2011298281B2/en active Active
- 2011-09-02 AR ARP110103226A patent/AR082892A1/es not_active Application Discontinuation
- 2011-09-02 EA EA201300311A patent/EA029277B1/ru not_active IP Right Cessation
- 2011-09-02 EP EP11749454.2A patent/EP2611830A1/en not_active Withdrawn
- 2011-09-02 KR KR1020137008330A patent/KR101844875B1/ko active IP Right Grant
- 2011-09-02 NZ NZ607394A patent/NZ607394A/en unknown
- 2011-09-02 UY UY0001033588A patent/UY33588A/es unknown
- 2011-09-02 CA CA2808696A patent/CA2808696C/en active Active
- 2011-09-02 EP EP13190391.6A patent/EP2727939A3/en not_active Withdrawn
- 2011-09-02 BR BR112013005151-5A patent/BR112013005151A2/pt not_active Application Discontinuation
-
2013
- 2013-02-19 IL IL224800A patent/IL224800B/en active IP Right Grant
- 2013-03-01 CL CL2013000596A patent/CL2013000596A1/es unknown
-
2015
- 2015-12-18 US US14/974,343 patent/US20160200806A1/en not_active Abandoned
-
2017
- 2017-12-05 US US15/831,754 patent/US20180201671A1/en not_active Abandoned
-
2020
- 2020-06-17 US US16/903,888 patent/US20200308267A1/en not_active Abandoned
-
2022
- 2022-06-21 US US17/844,812 patent/US20220363744A1/en not_active Abandoned
-
2024
- 2024-01-11 US US18/409,969 patent/US20240141030A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EA201300311A1 (ru) | 2013-08-30 |
EP2611830A1 (en) | 2013-07-10 |
IL224800B (en) | 2020-03-31 |
JP2013541939A (ja) | 2013-11-21 |
UY33588A (es) | 2012-03-30 |
BR112013005151A2 (pt) | 2020-08-04 |
AR082892A1 (es) | 2013-01-16 |
CA2808696C (en) | 2016-12-20 |
KR101844875B1 (ko) | 2018-04-03 |
NZ607394A (en) | 2014-12-24 |
US20200308267A1 (en) | 2020-10-01 |
KR20130101045A (ko) | 2013-09-12 |
US20240141030A1 (en) | 2024-05-02 |
CL2013000596A1 (es) | 2014-02-14 |
EP2727939A3 (en) | 2014-05-21 |
CN103209995B (zh) | 2015-11-25 |
JP5979504B2 (ja) | 2016-08-24 |
AU2011298281B2 (en) | 2015-02-05 |
EP2727939A2 (en) | 2014-05-07 |
AU2011298281A1 (en) | 2013-03-14 |
CA2808696A1 (en) | 2012-03-08 |
US20160200806A1 (en) | 2016-07-14 |
US20120225081A1 (en) | 2012-09-06 |
CN103209995A (zh) | 2013-07-17 |
US20220363744A1 (en) | 2022-11-17 |
WO2012028716A1 (en) | 2012-03-08 |
EA029277B1 (ru) | 2018-03-30 |
MX353813B (es) | 2018-01-31 |
US20180201671A1 (en) | 2018-07-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2013002379A (es) | Moleculas de union a vegf. | |
PH12014502179A1 (en) | Ang2-binding molecules | |
TN2012000144A1 (en) | Dll4-binding molecules | |
TN2012000145A1 (en) | Bispecific binding molecules for anti-angiogenesis therapy | |
TN2013000390A1 (en) | Bispecific binding molecules binding to vegf and ang2 | |
SA518400424B1 (ar) | جزيئات الجسم المضاد لعلاج السرطان | |
WO2011143624A3 (en) | Humanized and chimeric monoclonal antibodies to cd47 | |
PH12018500639A1 (en) | Optimized monoclonal antibodies agaist tissue factor pathway inhibitor (tfpi) | |
PH12014502527A1 (en) | St2 antigen binding proteins | |
WO2014004549A3 (en) | Anti-mesothelin binding proteins | |
MX2015008446A (es) | Composiciones de proteinas de union multivalentes. | |
TN2014000360A1 (en) | Cx3cr1-binding polypeptides | |
TN2013000389A1 (en) | BISPECIFIC BINDING MOLECULES BINDING TO Dll4 AND Ang2 | |
WO2012135671A3 (en) | Monoclonal antibodies against tissue factor pathway inhibitor (tfpi) | |
WO2011085134A8 (en) | Methods and compositions for the diagnosis, prognosis and treatment of cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |